Skip to content
Screener

Rhythm Pharmaceuticals, Inc. RYTM License revenue — Total revenues

Similar metrics at other companies

Quanterix Corporation logo
QTRXCollaboration and license revenue — Total revenues
$560K-27.4%
Acacia Research logo
ACTGRecurring license revenue agreements — Total revenues
$313K-4.9%
Exelixis logo
EXELLicense revenues — Total revenues
$59.81M+21.3%
MicroStrategy logo
MSTRLicense — Total revenues
$5.5M-24.3%
Intapp, Inc. logo
INTALicense — Total revenues
$24.79M-21.7%
Open Text logo
OTEXLicense — Total revenues
$214.61M+24.4%

Other financials

Income statement

See full
Revenue$60.1M+83.8%
Gross profit$53.0M+82.3%
Operating income-$52.4M-11.4%
Net income-$55.6M-12.4%
EPS (diluted)-$0.83-2.5%

Balance sheet

See full
Cash & equivalents$62.1M-41.4%
Total debt$112.3M-1.1%
Total equity$122.9M+549%
Total assets$442.3M+14.4%

Cash flow

See full
Operating cash flow-$44.2M-9.5%
CapEx$238.3K
Free cash flow-$29.2M-2.4%

Valuation

See full
Market cap$7.62B+27.5%
Enterprise value$7.67B+28.8%
P/S35.1×-3.2×

Profitability

See full
Gross margin89.4%-0.2pp
Operating margin-90.9%-19.8pp
Net margin-93.3%-18.2pp
FCF margin-61.5%-14.1pp

Returns & leverage

See full
Return on equity-285.8%-68.9pp
Debt / equity0.9×-5.1×
Current ratio4.2×+0.9×

Where this comes from

Reported directly by Rhythm Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Rhythm Pharmaceuticals, Inc.’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:15 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-030549
Line itemThree months ended March 31, 20262025
Revenues:
Product revenue, net$60,112$37,718
License revenue(5,014)
Total revenues60,11232,704
Costs and expenses:
Cost of sales7,1573,648
Research and development41,72536,973
Selling, general, and administrative63,59139,087

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Rhythm Pharmaceuticals, Inc.'s license revenue — total revenues?
Rhythm Pharmaceuticals, Inc. (RYTM) reported license revenue — total revenues of $0 in Q1 2026.
How has Rhythm Pharmaceuticals, Inc.'s license revenue — total revenues changed year-over-year?
Rhythm Pharmaceuticals, Inc.'s license revenue — total revenues increased by 100.0% year-over-year, from -$5.01M to $0.
What is the long-term trend for Rhythm Pharmaceuticals, Inc.'s license revenue — total revenues?
Over 2 years (2022 to 2024), Rhythm Pharmaceuticals, Inc.'s license revenue — total revenues has grown at a -100.0% compound annual growth rate (CAGR), from $6.8M to $0.
What does license revenue — total revenues mean?
This metric represents the revenue generated from licensing intellectual property, technology, or drug candidates to third-party partners. It reflects the company's ability to monetize its research and development pipeline through strategic partnerships rather than direct product sales. Fluctuations in this metric indicate the timing and success of milestone payments, upfront fees, or royalty arrangements within the biopharmaceutical business model.

Ask your AI about Rhythm Pharmaceuticals, Inc.'s license revenue — total revenues.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude